Kingsview Wealth Management’s Biogen BIIB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$421K Buy
1,865
+694
+59% +$147K 0.01% 1037
2026
Q2
$253K Buy
1,171
+15
+1% +$2.87K ﹤0.01% 1262
2026
Q1
$212K Buy
+1,156
New +$213K ﹤0.01% 1228
2023
Q3
– Sell
-1,101
Closed -$314K – 935
2023
Q2
$314K Buy
+1,101
New +$328K 0.01% 727
2017
Q4
– Sell
-762
Closed -$239K – 398
2017
Q3
$239K Buy
+762
New +$226K 0.11% 239

Other funds holding BIIB

Kingsview Wealth Management's BIIB Position: Q3 2026 in Review

Kingsview Wealth Management increased its Biogen (BIIB) stake by 59% in Q3 2026, buying an estimated $147K and bringing the position to 1,865 shares worth $421K. The position accounts for 0.01% of the portfolio, ranked #1037.

Kingsview Wealth Management first reported a position in BIIB in Q3 2017 and has held it in 5 quarters since. 1,062 funds tracked by Wall St. Rank hold BIIB as of Q3 2026.

  • Kingsview Wealth Management held 1,865 shares of Biogen worth $421K as of Q3 2026.
  • Kingsview Wealth Management bought 694 Biogen shares in Q3 2026, an estimated $147K.
  • Biogen made up 0.01% of Kingsview Wealth Management's portfolio in Q3 2026, its #1037 holding.
  • Kingsview Wealth Management first reported a position in Biogen in Q3 2017 and has held it in 5 quarters since.
  • 1,062 funds tracked by Wall St. Rank held Biogen as of Q3 2026.

Based on Kingsview Wealth Management's 13F filing for Q3 2026, filed 13 Nov 2026.